Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

U.S. stocks moved higher on Monday as optimism around earnings overshadowed any investor fears over the latest developments ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

Though there were no historical benchmarks to gauge the response, the Dollar Index could fall more than 5%. Sterling edged higher versus the euro but remained weaker against a firmer dollar after the ...

After rolling through March and April, Lucid stock encountered resistance again in May. Early in the month, the company reported Q1 2025 financial results that jump-started a sell-off in Lucid stock.

A modest pullback for U.S. stocks Friday eased the market from all-time highs and left major stock indexes on Wall Street in the red for the week. The S&P 500 closed 0.3% lower a day after setting ...

THE LAWSUIT: A class action securities lawsuit was filed against Sarepta Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...

[SMM Analysis: Declining Operating Rates + Spreading Price Wars — Challenges Persist in the PV Frame Extrusion Industry] This week, the operating rate of PV frame extrusion among sampled enterprises ...